Related references
Note: Only part of the references are listed.Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
David Devos et al.
ANTIOXIDANTS & REDOX SIGNALING (2014)
Automation of o-dianisidine assay for ceruloplasmin activity analyses: usefulness of investigation in Wilson's disease and in hepatic encephalopathy
Mariacristina Siotto et al.
JOURNAL OF NEURAL TRANSMISSION (2014)
Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease
Scott Ayton et al.
ANNALS OF NEUROLOGY (2013)
Regional siderosis: a new challenge for iron chelation therapy
Zvi Ioav Cabantchik et al.
FRONTIERS IN PHARMACOLOGY (2013)
The history of the research of iron in parkinsonian substantia nigra
Andrzej Friedman et al.
JOURNAL OF NEURAL TRANSMISSION (2012)
Ceruloplasmin Oxidation, a Feature of Parkinson's Disease CSF, Inhibits Ferroxidase Activity and Promotes Cellular Iron Retention
Stefano Olivieri et al.
JOURNAL OF NEUROSCIENCE (2011)
Intracellular labile iron
William Breuer et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2008)
Comparison of two automated spectrophotometric methods for ceruloplasmin measurement in pigs
S. Martinez-Subiela et al.
RESEARCH IN VETERINARY SCIENCE (2007)
Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease
H Hochstrasser et al.
NEUROLOGY (2004)
Share Paper
